Profile | GDS2987 / GI_39777593-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 194.1 | 83 |
GSM215244 | HMVEC_vehicle_rep2 | 190.6 | 82 |
GSM215253 | HMVEC_vehicle_rep3 | 179.1 | 82 |
GSM215254 | HMVEC_atorvastatin_rep1 | 764.8 | 93 |
GSM215282 | HMVEC_atorvastatin_rep3 | 632.4 | 92 |
GSM215344 | HMVEC_atorvastatin_rep2 | 592.3 | 91 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 193.3 | 82 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 224.6 | 83 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 189.2 | 81 |
GSM215294 | HMVEC_SLx2119_rep1 | 349.5 | 88 |
GSM215295 | HMVEC_SLx2119_rep2 | 403.6 | 88 |
GSM215296 | HMVEC_SLx2119_rep3 | 427.9 | 89 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 16 | 28 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 18.7 | 31 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 2.5 | 5 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 13.7 | 23 |
GSM215327 | PASMC_SLx2119_rep1 | 17.1 | 30 |
GSM215328 | PASMC_SLx2119_rep2 | 24.3 | 41 |
GSM215329 | PASMC_SLx2119_rep3 | 21.7 | 39 |
GSM215330 | Fibroblasts_vehicle_rep1 | 72.2 | 72 |
GSM215331 | Fibroblasts_vehicle_rep2 | 74 | 72 |
GSM215332 | Fibroblasts_vehicle_rep3 | 56 | 70 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 53.5 | 69 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 75.5 | 72 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 55.1 | 69 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 88.4 | 74 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 70.2 | 72 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 64.2 | 71 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 68 | 72 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 71.2 | 72 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 72.5 | 72 |